Pfizer Plans Obesity Drug Launch Drawing on Viagra Rollout Experience

Pfizer is drawing on lessons learned from rolling out Viagra as it maps out the launch of its first obesity medicine. The parallels between weight loss and erectile dysfunction—two sensitive health topics influenced by social perceptions—are among the factors helping to inform the drugmaker as it considers how best to introduce the monthly injection just gained from its acquisition of Metsera Inc., according to the company's chief international commercial officer.

The pharmaceutical giant is navigating a complex transitional period as revenues from its COVID-related products diminish and key patent cliffs approach. The company is making a substantial strategic bet on the lucrative obesity drug market. Pfizer's revenue forecast for the full year 2026 stands between $59.5 and $62.5 billion, a figure below its 2025 performance. This decline is primarily driven by the ongoing reduction in COVID-19 product sales (Comirnaty and Paxlovid), which are projected to fall to approximately $5 billion—a fraction of their pandemic-era peaks.

In early February 2026, the company announced positive data from a Phase 2b clinical trial (VESPER-3) for a novel drug candidate. A potential key differentiator from established treatments by Novo Nordisk and Eli Lilly is its dosing frequency: Pfizer's candidate aims for a monthly injection schedule, contrasting with the weekly regimens of current market leaders. The study demonstrated a weight-reducing effect of up to 12.3%, positioning the drug as a potentially competitive product.

To accelerate its path to market, Pfizer has planned an extensive clinical program involving more than 20 studies this year alone, with the goal of securing regulatory approval by 2028. Success would provide a compelling option for patients seeking a less frequent dosing schedule. A key near-term event for investors is scheduled for June 6, when detailed results from the VESPER-3 study will be presented at the American Diabetes Association meeting.

Compounding financial pressures is the impending loss of exclusivity for several blockbuster drugs. Major revenue drivers, including the blood thinner Eliquis and the cancer treatment Ibrance, are set to face generic competition in the period leading up to 2030. Market analysts view the stock's current valuation, trading at a price-to-earnings ratio of just under 9, as a reflection of these substantial risks. The shares recently traded at €23.30, having recovered somewhat from their 52-week low of €19.28.

For shareholders willing to wait, the company's dividend policy offers a measure of compensation. Pfizer recently distributed its 349th consecutive quarterly dividend. The current dividend yield of 6.2% acts as a buffer for investors while the company executes its strategic transformation. Beyond obesity, Pfizer has also recorded recent successes in oncology, notably securing full FDA approval for a combination therapy targeting colorectal cancer.